文献速递血栓与止血

艾美赛珠单抗预防治疗期间自发性关节出血的预测参数

Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis.
PubMed 文献 · Blood Adv · 2024-01-01

本研究为观察性队列研究,纳入40例接受艾美赛珠单抗预防治疗的重型A型血友病患者(伴或不伴抑制物),其中10例发生自发性关节出血。实验室参数均无法区分出血高风险患者,ROC分析显示仅滑膜炎存在和HEAD-US评分较高与自发性关节出血相关(曲线下面积0.84)。

要点

  • 40例接受艾美赛珠单抗预防治疗的重型A型血友病患者中,10例发生自发性关节出血。
  • 凝血酶生成试验、血栓弹力图及艾美赛珠单抗浓度均无法区分自发性关节出血高风险患者。
  • 仅滑膜炎存在和HEAD-US评分较高与自发性关节出血相关,曲线下面积0.84。

核心结论

  • 更严重的关节病变和滑膜炎存在可帮助预测接受艾美赛珠单抗预防治疗的A型血友病患者发生自发性关节出血的风险。

研究设计与样本

  • 观察性队列研究,纳入40例接受艾美赛珠单抗预防治疗的重型A型血友病患者,伴或不伴抑制物。

主要发现

  • 40例患者中10例发生自发性关节出血。
  • 所有实验室参数均无法区分自发性关节出血高风险患者。
  • ROC分析显示,艾美赛珠单抗预防治疗期间仅滑膜炎存在和HEAD-US评分较高与自发性关节出血相关,曲线下面积0.84。

关键数值与推荐

  • 凝血酶生成试验在加入组织因子和合成磷脂后进行。
  • 非活化血栓弹力图在枸橼酸化全血上进行。
  • 艾美赛珠单抗浓度采用改良一步法凝血因子VIII测定。
  • 关节病变程度采用血友病关节健康评分和血友病早期关节病变超声检测(HEAD-US)评分评估。
  • 采用Cox比例风险模型评估变量与出血之间的关联,采用ROC分析研究这些变量的预测能力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emicizumab is approved for prophylaxis of patients with hemophilia A (HA). Despite its efficacy in reducing bleeding, some patients on emicizumab still experience hemarthrosis, but no tool is yet available to identify those at a higher risk of spontaneous joint bleeding. This study aimed to evaluate whether laboratory measurements (global coagulation assays and emicizumab concentration) and/or arthropathy scores can distinguish patients at higher risk of spontaneous joint bleeding while on emicizumab prophylaxis. A thrombin generation assay was performed upon the addition of tissue factor and synthetic phospholipids. Nonactivated thromboelastography was performed on citrated whole blood. Emicizumab concentrations were measured using a modified 1-stage factor VIII assay. The degree of hemophilic arthropathy was assessed using the Hemophilia Joint Health Score and Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score. A Cox proportional hazards model was used to evaluate the association between variables and bleeding. The predictive power of these variables was investigated using receiver operating characteristic (ROC) analysis. Forty patients with severe HA, with or without inhibitors, on emicizumab prophylaxis were enrolled in an observational cohort study. Ten of 40 developed spontaneous joint bleeding. None of the laboratory parameters were able to distinguish patients with a higher risk of spontaneous joint bleeding. ROC analysis showed that during emicizumab prophylaxis, only the presence of synovitis and a higher HEAD-US score were associated with spontaneous joint bleeding (area under the curve, 0.84). A greater degree of arthropathy and the presence of synovitis could help predict the risk of spontaneous joint bleeding in patients with HA on emicizumab prophylaxis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Arcudi S, Gualtierotti R, Scalambrino E, et al. Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis. Blood Adv. 2024. PMID: 38531053. doi:10.1182/bloodadvances.2023012285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。